Lentykine 4 Capsule contains Lenvatinib 4 mg, a potent multi-kinase inhibitor indicated for the treatment of various malignancies including differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma. Lenvatinib exerts its therapeutic effect by selectively inhibiting vascular endothelial growth factor receptors (VEGFR 1-3), fibroblast growth factor receptors (FGFR 1-4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT signaling pathways, thereby impeding tumor angiogenesis and proliferation. Lentykine 4 Capsule is administered orally and is typically prescribed as part of a comprehensive oncology treatment regimen under specialist supervision. Dosage and duration depend on the specific cancer type, patient response, and tolerability. Common adverse effects include hypertension, fatigue, diarrhea, decreased appetite, weight loss, and proteinuria; therefore, regular monitoring of blood pressure, renal function, and liver enzymes is recommended during therapy. Dose adjustments or temporary discontinuation may be necessary in case of severe toxicity. Lentykine 4 Capsule should be used with caution in patients with hepatic impairment or cardiovascular disease. It is contraindicated in pregnancy due to potential teratogenic effects. Healthcare professionals should counsel patients regarding adherence, potential side effects, and the importance of routine follow-up to optimize therapeutic outcomes.